iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Sold by Public Employees Retirement System of Ohio

Public Employees Retirement System of Ohio lessened its stake in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 21.6% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 28,826 shares of the company’s stock after selling 7,952 shares during the quarter. Public Employees Retirement System of Ohio’s holdings in iTeos Therapeutics were worth $294,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. XTX Topco Ltd acquired a new stake in shares of iTeos Therapeutics during the 3rd quarter worth about $186,000. Wellington Management Group LLP boosted its position in iTeos Therapeutics by 20.9% during the third quarter. Wellington Management Group LLP now owns 105,769 shares of the company’s stock worth $1,080,000 after acquiring an additional 18,255 shares during the last quarter. State Street Corp grew its stake in iTeos Therapeutics by 21.9% in the 3rd quarter. State Street Corp now owns 1,175,353 shares of the company’s stock worth $12,000,000 after acquiring an additional 211,452 shares during the period. Readystate Asset Management LP raised its holdings in iTeos Therapeutics by 97.2% in the 3rd quarter. Readystate Asset Management LP now owns 169,819 shares of the company’s stock valued at $1,734,000 after acquiring an additional 83,700 shares during the last quarter. Finally, Point72 DIFC Ltd purchased a new position in shares of iTeos Therapeutics during the 3rd quarter worth $31,000. Hedge funds and other institutional investors own 97.16% of the company’s stock.

Analyst Ratings Changes

ITOS has been the subject of a number of recent analyst reports. Wedbush reaffirmed an “outperform” rating and issued a $25.00 price objective on shares of iTeos Therapeutics in a research report on Thursday, December 12th. HC Wainwright restated a “buy” rating and issued a $21.00 price target on shares of iTeos Therapeutics in a report on Friday, December 13th. Finally, Wells Fargo & Company cut their price objective on shares of iTeos Therapeutics from $31.00 to $19.00 and set an “overweight” rating on the stock in a report on Thursday.

iTeos Therapeutics Trading Up 2.8 %

Shares of iTeos Therapeutics stock opened at $7.42 on Friday. The business’s fifty day moving average price is $8.54 and its 200 day moving average price is $12.62. iTeos Therapeutics, Inc. has a twelve month low of $7.09 and a twelve month high of $18.75. The stock has a market capitalization of $271.08 million, a P/E ratio of -2.36 and a beta of 1.37.

iTeos Therapeutics (NASDAQ:ITOS) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($1.05) earnings per share for the quarter, beating the consensus estimate of ($1.18) by $0.13. As a group, sell-side analysts predict that iTeos Therapeutics, Inc. will post -3.46 EPS for the current year.

Insider Buying and Selling at iTeos Therapeutics

In related news, CFO Matthew Gall purchased 5,000 shares of the firm’s stock in a transaction on Tuesday, November 19th. The stock was purchased at an average price of $7.73 per share, for a total transaction of $38,650.00. Following the acquisition, the chief financial officer now directly owns 65,429 shares in the company, valued at $505,766.17. The trade was a 8.27 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 12.50% of the stock is currently owned by corporate insiders.

About iTeos Therapeutics

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.